Please assess the completion status of the following clinical trial:

Trial Title: A Study of KW-6356 in Subjects With Early Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic criteria~* Parkinson's disease patients in Stages 1 to 3 on the Modified Hoehn and Yahr Scale~* MDS-UPDRS part III score of ≥ 15~Exclusion Criteria:~* Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment.~* Use of any of the specified antiparkinsonian drugs and dopamine antagonists during the specified period.~* Treatment with levodopa/DCI at any time in the past for a period of 4 weeks or more.~* Neurosurgical operation for Parkinson's disease (stereotactic surgery, deep brain stimulation or gamma knife), or treatment by transcranial magnetic stimulation (TMS).~* Either of the following criteria consecutively at screening and enrollment;~  * Resting Pulse \> 100 bpm~ * Resting systolic blood pressure \> 140 mmHg, or diastolic blood pressure \> 90 mmHg~* Significant dementia or a Mini-Mental State Examination (MMSE) score of ≤ 23.~* Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline.~* Anyone otherwise considered unsuitable for the study by the investigator or sub-investigator including those who are unable to communicate or to cooperate with the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- KW-6356 Low Dose (Type: EXPERIMENTAL): Oral administration
- KW-6356 High Dose (Type: EXPERIMENTAL): Oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).